About Company

• q Incorporated in September 2002, Symbiotec Pharmalab is a research-driven pharmaceutical and biotechnology company with strengths in organic chemistry, biotechnology, and complex injectables, holding global leadership in corticosteroid APIs with 38.2% share and steroidal hormone APIs with 23.8% share in Fiscal 2026. The company evolved from a lab-scale steroidal hormone API manufacturer in 1995 into a backward-integrated platform approved by US FDA, EU GMP, and other regulators, operating as a CDMO for global pharmaceutical and nutraceutical companies.
• q As of March 31, 2026, they had two API facilities with 584.67 MT chemical synthesis and 300 KL fermentation capacity, expanded with Ujjain and Mhow facilities to 700 KL fermentation and 20 million vials of injectables annually, with a proposed 14 KL biologics unit for GLP-1 and Insulin. Their portfolio includes over 60 APIs such as Hydrocortisones, Betamethasones, Methylprednisolones, Progesterones, Estrogens, and Testosterones, with global leadership in Hydrocortisone (80.1%), Testosterone (76.4%), and Methylprednisolone (76%).
• q Rau houses corticosteroid API blocks approved by global regulators; Pithampur has isolated hormone and corticosteroid blocks with four 5 KL and eight 35 KL fermenters.
• q Over three fiscals, Symbiotec invested ?798.61 crore to expand API and injectables capacity and signed contracts to supply complex biotechnology products worldwide.
• q The company holds 43 US FDA drug master files and 23 EDQM certificates, with differentiated chemistry enabling up to 400 synthesis steps under cGMP. They are among the few globally developing conjugated estrogens, collaborating with a specialty pharmaceutical company for milestone payments and profit sharing. Their backward integration covers over 80% of products by revenue, using microbial strains to produce steroid and hormone precursors.
• q Fermentation capabilities span biotransformation of soy sterols, classical fermentation for anti-infectives and enzymes, recombinant protein expression for GLP-1 and Insulin, and precision fermentation for nutraceuticals and alternate proteins. The company supplies products through three verticals—API products, CDMO services, and complex injectables—serving over 200 customers in 40+ countries. Their forward integration centres on double chamber vials, bags, and syringes, scaled for commercial execution using in-house materials.

Strengths

Competitive Strength 

• Global leadership in corticosteroid and steroidal-hormone APIs
• Long-standing relationships with domestic and global customer base
• Fully-invested, multi-scale, vertically integrated manufacturing platform with sustainable practices and clean regulatory track record
• Continuous investment in R&D, with leading technological capabilities among Indian peers
• Ability to leverage science and existing competencies to increase total addressable market and deepen intellectual property-driven offerings
• Robust financials with strong gross margins, high capital efficiency and cash conversion
• Seasoned leadership team supported by strong pool of experienced management and marquee investors

Business Strategies 

• Build on their global leadership by expanding the product portfolio across steroidal-hormones in their own API and ingredients business
• Build on fermentation capabilities and expand biotechnology offerings such as GLP-1 and Insulin
• Commercialize complex injectables through differentiated drug device combinations
• Scale up their diverse CDMO offerings based on their three interlinked differentiated platform technologies
• Continue to invest in new technologies, R&D for optimising products, building on historical innovation ethos
• Partner with large companies for difficult-to-execute projects

Company Promoters

Company Financials

Objects of the Issue